Pre-made Gilvetmab benchmark antibody ( Canine Whole mAb, anti-PDCD1 (Canine) therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-243
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Gilvetmab biosimilar, Canine Whole Mab: Anti-PDCD1 (Canine) therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Gilvetmab biosimilar, Canine Whole Mab: Anti-PDCD1 (Canine) therapeutic antibody |
|---|---|
| INN Name | Gilvetmab |
| Target | PDCD1 (Canine) |
| Format | Canine Whole mAb |
| Derivation | Caninized |
| Species Reactivity | Canine |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Unknown |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | Merck |
| Conditions Approved | NA |
| Conditions Active | Canine Cancers |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | PDCD1 (Canine) |
| Package |
Previous slide
Next slide
